Search This Blog
Friday, October 5, 2018
Cytokinetics price target lowered to $21 from $24 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis lowered his price target on Cytokinetics shares to $21 from $24 after partner Astellas reported that both primary and secondary endpoints were not met in a trial of reldesemtiv in COPD patients and another trial testing reldesemtiv in elderly frailty was discontinued. However, omecamtiv drives the “lion’s share” of his valuation of Cytokinetics shares, said Pantginis. The analyst, who noted that the omecamtiv mecarbil pivotal
https://thefly.com/landingPageNews.php?id=2800479
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.